Non–small cell lung cancer (NSCLC) is one of the most prevalent cancers and is
responsible for a large proportion of all cancer-related deaths. Current treatment options are …

Introduction: Immune checkpoint inhibitors targeting programmed death protein 1 (PD-1)
receptor and its ligand, PD-L1, have recently led to significant and durable improvements in …

The last decade has witnessed rapid advances in the discovery and development of
immune checkpoint inhibitors in cancer medicine, particularly drugs targeting programmed …

Lung cancer is the leading cause of cancer-specific death among Canadians, with non-
small-cell lung cancer (NSCLC) being the most common histologic variant. Despite …

Background We assessed the efficacy and safety of programmed cell death 1 (PD-1)
inhibition with pembrolizumab in patients with advanced non–small-cell lung cancer …

Background Pembrolizumab plus platinum‐based chemotherapy has demonstrated
improved clinical outcomes over chemotherapy alone in patients with previously untreated …

Background Pembrolizumab is a humanized monoclonal antibody against programmed
death 1 (PD-1) that has antitumor activity in advanced non–small-cell lung cancer (NSCLC) …

The clinical development of immune checkpoint blockade has dramatically changed the
treatment paradigm and prognosis for patients with non–small cell lung cancer …

In recent years, immunotherapy has revolutionized and changed the standard of care in
patients with advanced non-small cell lung cancer (NSCLC). Immune checkpoint inhibitors …

The Food and Drug Administration (FDA) approval of immune checkpoint inhibitors has
dramatically changed treatment paradigms for patients with advanced-stage or metastatic …